Considering that BET inhibitors are in advanced clinical trials, and the MEK inhibitor trametinib is FDA‐approved for BRAF‐mutant melanoma patients, clinical studies combining BETi and MEKi could be rapidly implemented for therapy‐resistant melanoma, assessing a promising treatment strategy that could improve the outcomes of patients who have failed all currently available therapies. Here, BRAF is linked to melanoma.